SCHEMBL370320

SCHEMBL370320

COc1ccc(Cn2cc(C(=O)O)c(Br)n2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
CHRM1 P11229 2/20 0.47
CACNA1G O43497 2/20 0.46
CACNA1H O95180 2/20 0.46
CACNA1I Q9P0X4 2/20 0.46
MEN1 O00255 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
USP2 O75604 1/20 0.45
TP53 P04637 1/20 0.45
HDAC1 Q13547 1/20 0.45
AADAT Q8N5Z0 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
ATM Q13315 1/20 0.42
CMA1 P23946 1/20 0.42
PTGS2 P35354 1/20 0.42
FABP4 P15090 1/20 0.41
SNCA P37840 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
LDHA P00338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15182553 0.89 KMT2A (0.46) KMT2ACHRM1CACNA1GCACNA1HCACNA1I
SCHEMBL369567 0.89 KMT2A (0.46) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL370325 0.87 GSK3B (0.47) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL369424 0.86 UCHL1 (0.47) KMT2AMEN1USP2TP53HDAC1
SCHEMBL25205458 0.85 KMT2A (0.55) KMT2ACHRM1CACNA1GCACNA1HCACNA1I
SCHEMBL1047554 0.85 KMT2A (0.55) KMT2ACHRM1CACNA1GCACNA1HCACNA1I
SCHEMBL368611 0.84 CACNA1G (0.42) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL370507 0.83 KMT2A (0.53) KMT2ACHRM1CACNA1GCACNA1HCACNA1I
SCHEMBL370508 0.83 KMT2A (0.53) KMT2ACHRM1CACNA1GCACNA1HCACNA1I
SCHEMBL25334568 0.81 NPC1 (0.54) KMT2ACHRM1CACNA1GCACNA1HCACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS BOLEA CHRISTELLE (CH) 2013-08-15 US disclosed
EP-2595986-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2013-05-29 EP disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed
WO-2012009009-A2 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 KMT2A 1638/4885CHRM1 250/4885CACNA1G 353/4885
US-20130210809-A1 NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM2, GRM4, GRM1 KMT2A 1336/4885CHRM1 293/4885CACNA1G 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.